High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 09 2023
30 09 2023
Historique:
received:
22
02
2023
accepted:
20
09
2023
medline:
2
10
2023
pubmed:
1
10
2023
entrez:
30
9
2023
Statut:
epublish
Résumé
Tumor-associated high endothelial venules (TA-HEVs) mediate lymphocyte entry into tumors. Therefore, combined anti-angiogenesis therapy and programmed death-1 (PD-1) inhibitors might stimulate tumor immunity. This study will explore the TA-HEVs and real-world data of the combination therapy in non-small cell lung cancer (NSCLC). Firstly, we found a certain relationship between HEVs and immune effector cells by multiple immunofluorescence staining. We then analyzed the efficacy of immunotherapy combined with anti-angiogenesis therapy in advanced NSCLC patients by collecting real-world clinical data. Finally, we explored the predictive value of HEVs in combination therapy by analyzing pre-treatment pathological slides of patients with multiple immunofluorescence and RNA sequencing. Immunofluorescence staining of high endothelial venules (PNAd+) reveals that the frequency of HEVs is positively correlated with tumor-infiltrating stem-like CD8+ T cells (TCF-1+PD-1+) in the TME of advanced NSCLC patients (P = 0.0221). We retrospectively analyzed the efficacy of 96 patients with advanced NSCLC who received PD-1 inhibitors combined with anti-angiogenesis therapy in the real-world. The median PFS of patients combined with anti-angiogenesis therapy was longer than that of patients without anti-angiogenesis therapy (9.7 vs 8.6 months, P = 0.041). Multiple immunofluorescence staining of tumor biopsies before treatment from 14 patients with advanced NSCLC reveals that PNAd+ is predictive of better response and survival upon PD-1 inhibitors combined with anti-angiogenesis therapy (P = 0.0274). In addition, we collected peripheral blood from an effective group of patients for RNA sequencing and found that immune cells activation-related gene expression scores were higher. Combined anti-angiogenic and anti-PD-1 therapy stimulates tumor immunity through TA-HEVs formation. TA-HEVs not only mediate immune cell entry into tumors, but also are associated with the efficacy of PD-1 inhibitors and anti-angiogenesis therapy in NSCLC.
Identifiants
pubmed: 37777573
doi: 10.1038/s41598-023-43122-w
pii: 10.1038/s41598-023-43122-w
pmc: PMC10543372
doi:
Substances chimiques
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16468Informations de copyright
© 2023. Springer Nature Limited.
Références
Veerman, K., Tardiveau, C., Martins, F., Coudert, J. & Girard, J. P. Single-cell analysis reveals heterogeneity of high endothelial venules and different regulation of genes controlling lymphocyte entry to lymph nodes. Cell Rep. 11, 3116–3131. https://doi.org/10.1016/j.celrep.2019.02.042 (2019).
doi: 10.1016/j.celrep.2019.02.042
Thiriot, A. et al. Differential DARC/ACKR1 expression distinguishes venular from non-venular endothelial cells in murine tissues. BMC Biol. 1, 45. https://doi.org/10.1186/s12915-017-0381-7 (2017).
doi: 10.1186/s12915-017-0381-7
Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 7791, 549–555. https://doi.org/10.1038/s41586-019-1922-8 (2020).
doi: 10.1038/s41586-019-1922-8
Blanchard, L. & Girard, J. P. High endothelial venules (HEVs) in immunity, inflammation and cancer. Angiogenesis 4, 719–753. https://doi.org/10.1007/s10456-021-09792-8 (2021).
doi: 10.1007/s10456-021-09792-8
Vella, G., Guelfi, S. & Bergers, G. High endothelial venules: A vascular perspective on tertiary lymphoid structures in cancer. Front. Immunol. https://doi.org/10.3389/fimmu.2021.736670 (2021).
doi: 10.3389/fimmu.2021.736670
pubmed: 34484246
pmcid: 8416033
Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 1, 195–211. https://doi.org/10.1016/j.immuni.2018.12.021 (2019).
doi: 10.1016/j.immuni.2018.12.021
Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 3, 326–336. https://doi.org/10.1038/s41590-019-0312-6 (2019).
doi: 10.1038/s41590-019-0312-6
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 4, 998–1013. https://doi.org/10.1016/j.cell.2018.10.038 (2018).
doi: 10.1016/j.cell.2018.10.038
Yi, M. et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer. 1, 60. https://doi.org/10.1186/s12943-019-0974-6 (2019).
doi: 10.1186/s12943-019-0974-6
Oguntade, A. S., Al-Amodi, F., Alrumayh, A., Alobaida, M. & Bwalya, M. Anti-angiogenesis in cancer therapeutics: The magic bullet. J. Egypt Natl. Canc. Inst. 1, 15. https://doi.org/10.1186/s43046-021-00072-6 (2021).
doi: 10.1186/s43046-021-00072-6
Basch, E. et al. Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin. Trials. 1, 104–114. https://doi.org/10.1177/1740774520975120 (2021).
doi: 10.1177/1740774520975120
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 4, 950–965 (2017). https://doi.org/10.1016/j.cell.2017.10.014 .
Taube, J. M. et al. Multi-institutional TSA-amplified multiplexed immunofluorescence reproducibility evaluation (MITRE) study. J. Immunother. Cancer. https://doi.org/10.1136/jitc-2020-002197 (2021).
doi: 10.1136/jitc-2020-002197
pubmed: 34266881
pmcid: 8286792
Webb, D. J. & Brown, C. M. Epi-fluorescence microscopy. Methods Mol. Biol. https://doi.org/10.1007/978-1-62703-056-4_2 (2013).
doi: 10.1007/978-1-62703-056-4_2
pubmed: 23026996
pmcid: 3483677
Lehmann, K. V., Kahles, A., Murr, M. & Ratsch, G. RNA instant quality check: Alignment-free RNA-degradation detection. J. Comput. Biol. 8, 857–866. https://doi.org/10.1089/cmb.2021.0603 (2022).
doi: 10.1089/cmb.2021.0603
Petitprez, F. et al. Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunol. Immunother. 6, 981–988. https://doi.org/10.1007/s00262-017-2058-z (2018).
doi: 10.1007/s00262-017-2058-z
Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 6, 1329–1339. https://doi.org/10.1158/1078-0432.CCR-14-1128 (2015).
doi: 10.1158/1078-0432.CCR-14-1128
Viratham, P. A. et al. A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Mol. Oncol. 10, 2384–2402. https://doi.org/10.1002/1878-0261.12764 (2020).
doi: 10.1002/1878-0261.12764
Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 6522, 1328–1334. https://doi.org/10.1126/science.abb9847 (2020).
doi: 10.1126/science.abb9847
Imyanitov, E. N., Iyevleva, A. G. & Levchenko, E. V. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit. Rev. Oncol. Hematol. https://doi.org/10.1016/j.critrevonc.2020.103194 (2021).
doi: 10.1016/j.critrevonc.2020.103194
pubmed: 33316418
Huang, Q. et al. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. Oncoimmunology. 12, e1396403. https://doi.org/10.1080/2162402X.2017.1396403 (2018).
doi: 10.1080/2162402X.2017.1396403
Horvath, L., Thienpont, B., Zhao, L., Wolf, D. & Pircher, A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Mol. Cancer. 1, 141. https://doi.org/10.1186/s12943-020-01260-z (2020).
doi: 10.1186/s12943-020-01260-z
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 1, 1–10. https://doi.org/10.1016/j.immuni.2013.07.012 (2013).
doi: 10.1016/j.immuni.2013.07.012
Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 4, 838–857. https://doi.org/10.1158/2159-8290.CD-20-1680 (2021).
doi: 10.1158/2159-8290.CD-20-1680
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 6382, 1350–1355. https://doi.org/10.1126/science.aar4060 (2018).
doi: 10.1126/science.aar4060
Jiang, W. et al. Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front. Immunol. https://doi.org/10.3389/fimmu.2020.622509 (2020).
doi: 10.3389/fimmu.2020.622509
pubmed: 33643289
pmcid: 7785707
Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1(+) neoantigen-specific CD8(+) T cells. Nat. Immunol. 1, 41–52. https://doi.org/10.1038/s41590-020-00810-3 (2021).
doi: 10.1038/s41590-020-00810-3
Jones, E., Gallimore, A. & Ager, A. Defining high endothelial venules and tertiary lymphoid structures in cancer. Methods Mol. Biol. https://doi.org/10.1007/978-1-4939-8709-2_7 (2018).
doi: 10.1007/978-1-4939-8709-2_7
pubmed: 30196498
pmcid: 6986360
Okayama, H. et al. Ectopic expression of MECA-79 as a novel prognostic indicator in gastric cancer. Cancer Sci. 5, 1088–1094. https://doi.org/10.1111/j.1349-7006.2011.01895.x (2011).
doi: 10.1111/j.1349-7006.2011.01895.x
Girard, J. P., Moussion, C. & Forster, R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat. Rev. Immunol. 11, 762–773. https://doi.org/10.1038/nri3298 (2012).
doi: 10.1038/nri3298
Martinet, L. et al. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin beta-producing dendritic cells in human breast cancer. J. Immunol. 4, 2001–2008. https://doi.org/10.4049/jimmunol.1300872 (2013).
doi: 10.4049/jimmunol.1300872
Allen, E. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aak9679 (2017).
doi: 10.1126/scitranslmed.aak9679
pubmed: 28794284
pmcid: 5723145
Rodriguez, A. B. & Engelhard, V. H. Insights into tumor-associated tertiary lymphoid structures: Novel targets for antitumor immunity and cancer immunotherapy. Cancer Immunol. Res. 11, 1338–1345. https://doi.org/10.1158/2326-6066.CIR-20-0432 (2020).
doi: 10.1158/2326-6066.CIR-20-0432